Monitor FDA decision on November 25, 2026, and EU regulatory progress. Positive outcome would open a new revenue stream in rare disease and strengthen Sanofi's lysosomal storage disorder portfolio. Adverse event profile appears manageable, but safety data from ongoing open-label phase is pending.
Price Chart
Executive Summary
Sanofi announced FDA priority review for venglustat NDA to treat type 3 Gaucher disease, with a target action date of November 25, 2026. The drug met both primary endpoints and three of four key secondary endpoints in the Phase 3 LEAP2MONO study. If approved, venglustat would be the first US treatment addressing neurological manifestations of GD3.
Key Facts
- FDA granted priority review for venglustat NDA for type 3 Gaucher disease
- Target action date for FDA decision is November 25, 2026
- Venglustat met both primary endpoints and three of four key secondary endpoints in Phase 3 LEAP2MONO study
- Venglustat previously received breakthrough therapy, fast-track, and orphan designations from FDA for GD3
- No approved targeted treatments currently exist for neurological symptoms of GD3 in the US
- Venglustat is also under regulatory review for GD3 in the EU, with additional global filings planned in 2026
Financial Impact
Potential first-in-class oral therapy for a rare disease with no current neurological treatment options; revenue contribution uncertain until approval and launch
Risk Factors
- FDA may not approve by target date or may require additional data
- Commercial adoption may be limited if pricing or reimbursement is unfavorable
- Competing therapies or alternative treatment modalities could emerge
- Safety signals from ongoing open-label phase could affect risk-benefit profile
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-260613 |
| Document: d123884d6k.htm | 0001193125-26-260613 |
| Document: 0001193125-26-260613-index-headers.html | 0001193125-26-260613 |
| Document: 0001193125-26-260613-index.html | 0001193125-26-260613 |
| Document: 0001193125-26-260613.txt | 0001193125-26-260613 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 6-K | $86.67 $89.80 | ▲ +3.61% | ▲ +0.29% | $84.82 (−2.13%) |
May 27, 2026 21w ago | 6-K | $86.69 $90.53 | ▲ +4.43% | ▲ +2.55% | $84.82 (−2.16%) |
Apr 27, 2026 26w ago | 6-K | $95.06 $88.00 | ▼ −7.43% | ▼ −12.20% | $84.82 (−10.77%) |
Apr 23, 2026 26w ago | 6-K | $92.44 $87.55 | ▼ −5.29% | ▼ −10.31% | $84.82 (−8.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers